Special Edition 2014, Issue 2, Part 2.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2014, Issue 2, Part 1.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2014, Issue 1, Part 2.

Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore discusses patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy with program director, Dr. Raymond Chung.

The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2014, Issue 1, Part 1.

Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore interviews Dr. David Nelson from the University of Florida about patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy.

The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Volume 3, Issue 12.

Mark S. Sulkowski, MD, Professor of Medicine, Medical Director, Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology at the Johns Hopkins University School of Medicine, Raymond T. Chung, Associate Professor of Medicine, Harvard Medical School, Director of Hepatology, Vice Chief of Gastroenterology at Massachusetts General Hospital, and Laurent Castera, MD, PhD, Department of Hepatology, Beaujon Hospital, AP-AP, INSERM U773 at the University of Paris-Diderot. Discuss new information presented at the 2014 European Association for the Study of the Liver (EASL) meeting, as well as non-invasive markers of liver disease.

The post Highlights from the 2014 EASL Meeting appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Volume 3, Issue 10.

David Thomas, MD, Professor of Medicine, and Director of the Division of Infectious Diseases at the Johns Hopkins University School of Medicine discusses HCV screening and natural history, in the form of case-study scenarios for the clinical practice.

The post HCV Screening and Natural History appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Volume 3, Issue 8.

Susanna Naggie, MD, Professor, Assistant Professor of Medicine, Department of Medicine – Infectious Diseases at Duke University School of Medince discusses the development of new therapies for treating hepatitis C infection, and news about hepatitis B from the 64th meeting of the American Association for the Study of Liver Disease, as well as case-study scenarios for the clinical practice.

The post Susanna Naggie, MD Discussed HBV and HCV Coverage at AASLD appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Volume 3, Issue 6.

Dr. Fabien Zoulim, MD, PhD, Professor, head of INSERM Viral Hepatitis Laboratory at the Medical School of Lyon, Lyon 1 University, Hepatology Department, Hospices Civils de Lyon in Lyon, France discusses the topic of HBV cure, in the form of case-study scenarios for the clinical practice.

The post Cure of Hepatitis B: Is it Achievable? appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Volume 3, Issue 4.

Dr. Anna Suk-Fong Lok, MD, FRCP, Professor in the Department of Internal Medicine and Director of Clinical Hepatology in the Division of Gastroenterology at the University of Michigan Health System discusses predictive models for cirrhosis in the form of case-study scenarios for the clinical practice.

The post The Role of Prediction Models: Best practices in Identifying Cirrhosis and HCC in Patients Infected with HBV appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.

Volume 3, Issue 2.

Dr. Mark Sulkowski from The Johns Hopkins University School of Medicine discusses advancements in hepatitis C therapy presented at EASL, as well as case-study scenarios for the clinical practice.

The post European Association for the Study of the Liver HCV Update appeared first on DKBmed Radio.

Hosted on Acast. See acast.com/privacy for more information.